About
Technology
Issues
FAQ
Links
Official Page
Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.